Exploring Flupentixol/Melitracen (Deanxit®) for Chronic Gastritis and Intestinal Flora in Patients with Anxiety and Depression

Authors

  • Haiming JI , Yuping LI , Ping HU, Libin ZHANG, & Qiuwen MA

Abstract

This study was designed to explore the clinical efficacy of deanxit® for chronic gastritis in patients with anxiety and depression and then to analyze the effects on intestinal flora as well as the mental
states of the patients; 140 patients with chronic gastritis having anxiety and depression were randomly divided into study and control group, with 70 patients in each group. The control group was given
teprenone® (geranylgeranylacetone) and the study group was given deanxit® combined with teprenone®.
The clinical effects and occurrence of adverse reactions were evaluated and compared. The Hamilton Anxiety Rating Scale (HAMA) and the Hamilton Depression Rating scale (HAMD) scores as well as the
changes in the number of intestinal flora in fresh feces pre- and post-treatment were compared. The total
effective rate of the study group was 90.00%, which was significantly higher than that of the control group
(77.14%, P = 0.012). Before treatment, there was no significant difference in the HAMA and HAMD
scores between the two groups (P > 0.05). However, the scores in the study group were significantly lower
than those in the control group (P = 0.024, 0.021) after treatment. No significant difference in the symptom
scores in both groups was found before treatment (P > 0.05), while the symptom scores in the study group
were significantly lower than those in the control group after treatment (P = 0.015). No significant difference in the number of Bifidobacterium, Lactobacillus, Escherichia coli and Enterococcus between the two
groups was observed before treatment (P > 0.05). However, the numbers of Bifidobacterium and Lactobacillus in the study group were significantly higher than those in the control group (P = 0.032, 0.036) after
treatment, while the numbers of Escherichia coli and Enterococcus were significantly lower comparing
with the control group (P = 0.042, 0.038). No serious adverse reactions were observed in both groups. The
combination of teprenone capsules and deanxit® can significantly improve the clinical effects in the patients with chronic gastritis along with anxiety and depression symptoms.

Published

2019-11-21

Issue

Section

Articles